ATAI Life Sciences N.V. (ATAI): Price and Financial Metrics


ATAI Life Sciences N.V. (ATAI): $3.14

-0.08 (-2.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATAI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATAI POWR Grades

  • ATAI scores best on the Growth dimension, with a Growth rank ahead of 65.85% of US stocks.
  • ATAI's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • ATAI ranks lowest in Quality; there it ranks in the 18th percentile.

ATAI Stock Summary

  • ATAI LIFE SCIENCES NV's stock had its IPO on June 18, 2021, making it an older stock than just 2.52% of US equities in our set.
  • ATAI's price/sales ratio is 762.94; that's higher than the P/S ratio of 99.62% of US stocks.
  • As for revenue growth, note that ATAI's revenue has grown -96.73% over the past 12 months; that beats the revenue growth of only 0.89% of US companies in our set.
  • Stocks that are quantitatively similar to ATAI, based on their financial statements, market capitalization, and price volatility, are LGVN, SEER, AI, IONQ, and MPWR.
  • Visit ATAI's SEC page to see the company's official filings. To visit the company's web site, go to www.atai.life.

ATAI Valuation Summary

  • In comparison to the median Healthcare stock, ATAI's EV/EBIT ratio is 127.5% lower, now standing at -2.2.
  • ATAI's price/sales ratio has moved NA NA over the prior 15 months.

Below are key valuation metrics over time for ATAI.

Stock Date P/S P/B P/E EV/EBIT
ATAI 2022-09-23 782.4 1.7 -2.7 -2.2
ATAI 2022-09-22 809.2 1.7 -2.8 -2.3
ATAI 2022-09-21 835.9 1.8 -2.9 -2.4
ATAI 2022-09-20 891.7 1.9 -3.1 -2.6
ATAI 2022-09-19 898.9 1.9 -3.1 -2.6
ATAI 2022-09-16 937.8 2.0 -3.2 -2.7

ATAI Price Target

For more insight on analysts targets of ATAI, see our ATAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.10 Average Broker Recommendation 1.38 (Strong Buy)

ATAI Stock Price Chart Interactive Chart >

Price chart for ATAI

ATAI Price/Volume Stats

Current price $3.14 52-week high $17.81
Prev. close $3.22 52-week low $2.95
Day low $3.14 Volume 547,000
Day high $3.37 Avg. volume 857,897
50-day MA $4.17 Dividend yield N/A
200-day MA $4.91 Market Cap 520.85M

ATAI Life Sciences N.V. (ATAI) Company Bio


Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.


ATAI Latest News Stream


Event/Time News Detail
Loading, please wait...

ATAI Latest Social Stream


Loading social stream, please wait...

View Full ATAI Social Stream

Latest ATAI News From Around the Web

Below are the latest news stories about ATAI LIFE SCIENCES NV that investors may wish to consider to help them evaluate ATAI as an investment opportunity.

atai Life Sciences to Participate in September Investor Events

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi’s 17th Annual BioPharma Conference in BostonFormat: Industry PanelDate and Time: Wednesday, September 7th, 10:30 a.m. ET – 11:15 a.m. ETConference Link: URL H.C. Wainwright’s 24th Annual Global Investment Conference

Yahoo | September 6, 2022

7 Psychedelics Stocks to Buy for a Big Drug Boom

These are the seven psychedelics stocks to buy in September.

Tezcan Gecgil on InvestorPlace | August 30, 2022

Maxim Group Sticks to Their Buy Rating for ATAI Life Sciences (ATAI)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ATAI Life Sciences (ATAI - Research Report), with a price target of $12.00. The company's shares closed yesterday at $4.52.McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Capricor Therapeutics, and VistaGen Therapeutics. According to TipRanks, McCarthy has an average return of -38.3% and a 14.97% success rate on recommended stocks. ATAI Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $27.67, which is a 512.17% upside from current levels. In a report released on August 18, H.C.

Howard Kim on TipRanks | August 20, 2022

H.C. Wainwright Sticks to Their Buy Rating for ATAI Life Sciences (ATAI)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences (ATAI - Research Report) today and set a price target of $50.00. The company's shares closed yesterday at $4.53.According to TipRanks, Trucchio is an analyst with an average return of -7.6% and a 41.39% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Alnylam Pharma, and Arrowhead Pharmaceuticals.Currently, the analyst consensus on ATAI Life Sciences is a Moderate Buy with an average price target of $35.50.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $17.90 and a one-year low of $2.95.

Ryan Adist on TipRanks | August 18, 2022

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

- Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections- Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI) study of PCN-101, database lock for the GRX-917 Phase 1 trial, completion of SAD portion of ongoing KUR-101 Phase 1 trial,

Yahoo | August 15, 2022

Read More 'ATAI' Stories Here

ATAI Price Returns

1-mo -32.91%
3-mo -14.67%
6-mo -38.31%
1-year -79.97%
3-year 88.67%
5-year 517.02%
YTD -58.85%
2021 N/A
2020 N/A
2019 0.00%
2018 85.86%
2017 37.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6067 seconds.